PDF(Pubmed)
Abstract：
Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Currently, several biomarkers are being used as CLL prognosticators, including elevated protein levels, elevated RNA levels, gene mutations, and epigenetic changes. Materials and Methods: This study is a prospective study conducted on 55 patients newly diagnosed with CLL, serum IL-6 level was measured initially and after a 6-month treatment course. Correlation with the course of the disease and the known CLL prognostic parameters was done initially and after 6 months. Results: The initial serum IL-6 level in the patient group (pre-treatment) ranges from 36-91 pg/mL (median 57), and in the patient group (post-treatment) ranges from 1-32 pg/mL (median 2). Serum IL-6 level was positively correlated with WBC count, β2 microglobulin, LDH, ESR, B symptoms, Uric Acid, BM Aspirate (% of lymphocytes), and Binet and Rai staging systems. Conclusion: Serum IL-6 is a useful poor prognostic marker in newly diagnosed CLL patients; its prognostic value goes with the other known prognostic markers such as the BM lymphocyte count, ESR, and LDH.
摘要：
背景：慢性淋巴细胞白血病（CLL）是成人最常见的白血病。目前,几种生物标志物被用作CLL预测因子，包括蛋白质水平升高，RNA水平升高，基因突变,和表观遗传变化。材料和方法：本研究是一项前瞻性研究，对55例新诊断为CLL的患者进行，最初和治疗6个月后测量血清IL-6水平。最初和6个月后进行与病程和已知CLL预后参数的相关性。结果：患者组（治疗前）的初始血清IL-6水平范围为36-91pg/mL（中位数为57），患者组（治疗后）的范围为1-32pg/mL（中位数2）。血清IL-6水平与白细胞计数呈正相关,β2微球蛋白，LDH,ESR,B症状,尿酸,BM吸出（淋巴细胞的百分比），以及Binet和Rai分期系统。结论:血清IL-6是新诊断CLL患者的一个有用的不良预后标志物;其预后价值与其他已知的预后标志物如BM淋巴细胞计数,ESR,LDH。
